Clinical trial
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
NCT00254917 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00254917 |
|---|---|
| Title | Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Polio, Pertussis, Haemophilus Influenzae Type B |
| Intervention type | Biological |
| Interventions | Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine |
| Enrollment | 387 |
| Start date | Oct 1, 2003 |
| Primary completion | Feb 1, 2006 |
| Completion | Feb 1, 2006 |
| First posted | Nov 17, 2005 |
| Last update posted | Apr 16, 2012 |
| Countries | Philippines |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: